- Details
- Description
Packaging Size:
Durvalumab 500 mg
Strength:
500 mg / 10 mL (50 mg/mL)
Composition:
Durvalumab 500 mg
Treatment:
Immunotherapy used for certain lung cancers, hepatocellular carcinoma (liver cancer), biliary tract cancer, and urothelial/bladder cancer, depending on the approved indication and treatment regimen.
Form:
Concentrate for solution for IV infusion
Brand:
Imfinzi
Manufacturer:
AstraZeneca AB
Imfinzi 500 mg / 10 mL (Durvalumab 500 mg) is an intravenous immunotherapy medicine used to treat certain types of cancer. Its active ingredient, durvalumab, is a monoclonal antibody and PD-L1 immune checkpoint inhibitor that helps the immune system recognize and attack cancer cells. It is used for several approved cancer indications, including certain lung, liver, biliary tract, and urothelial cancers, depending on the specific diagnosis and treatment regimen. Imfinzi is administered by intravenous infusion under the supervision of a qualified healthcare professional.
Note: Imfinzi 500 mg/10 mL is a prescription oncology medicine supplied as a single-dose vial for dilution and intravenous infusion
